STOCK TITAN
  1. Home
  2. Sec-filings
  3. AURA
  4. [Form 4] Aura Biosciences, Inc. Insider Trading Activity

Matrix Capital fund exits 6.9M Aura Biosciences (AURA) shares in open-market sale

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Aura Biosciences, Inc. reported a large insider sale of its common stock connected to Matrix Capital entities. Matrix Capital Management Master Fund, LP sold 6,922,870 shares of common stock at $5.64 per share in an open-market transaction on May 7, 2026.

The shares are held by Matrix Capital Management Master Fund, LP, with Matrix Capital Management Company, LP as investment adviser and David E. Goel as managing general partner. The reporting persons indicate that the reported position is now zero shares and expressly disclaim beneficial ownership beyond any pecuniary interest.

Positive

  • None.

Negative

  • Large shareholder exit: A Matrix Capital–associated fund conducted an open-market sale of 6,922,870 Aura Biosciences common shares at $5.64, with the filing showing zero shares remaining for this reported holding, indicating a complete disposal of this position.

Insights

Large Matrix-linked fund fully exits reported Aura Biosciences position.

A Matrix Capital–associated fund sold 6,922,870 shares of Aura Biosciences common stock at $5.64 per share in an open-market transaction on May 7, 2026. The filing shows zero shares remaining for this reported holding.

The reporting persons, including Matrix Capital Management Company, LP and David E. Goel, classify the stake as indirect and expressly disclaim beneficial ownership except for any pecuniary interest. This is a sizable net-sell event in a single trade, and no remaining derivative positions are disclosed in this filing.

Insider Matrix Capital Management Company, LP, GOEL DAVID E.
Role null | null
Sold 6,922,870 shs ($39.04M)
Type Security Shares Price Value
Sale Common Stock, par value $0.00001 per share (Common Stock) 6,922,870 $5.64 $39.04M
Holdings After Transaction: Common Stock, par value $0.00001 per share (Common Stock) — 0 shares (Indirect, See footnotes)
Footnotes (1)
  1. The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager. The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Shares sold 6,922,870 shares Open-market sale on May 7, 2026
Sale price $5.64 per share Common stock transaction price
Shares after transaction 0 shares Total shares following reported transaction
Par value $0.00001 per share Aura Biosciences common stock par value
Common Stock, par value $0.00001 per share (Common Stock) financial
"security_title: Common Stock, par value $0.00001 per share (Common Stock)"
ten percent owner financial
"Matrix Capital Management Company, LP is marked as a ten percent owner"
pecuniary interest financial
"Reporting persons disclaim beneficial ownership except to the extent of pecuniary interest"
Section 16 of the Securities Act of 1934, as amended regulatory
"Footnote states filing is not an admission of beneficial ownership for purposes of Section 16"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Matrix Capital Management Company, LP
(Last)(First)(Middle)
C/O MATRIX CAPITAL MANAGEMENT
3 PLEASANT STREET, SUITE 400
(Street)
PORTSMOUTH NEW HAMPSHIRE 03801
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.00001 per share (Common Stock)05/07/2026S6,922,870D$5.640ISee footnotes(1)(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
Matrix Capital Management Company, LP
(Last)(First)(Middle)
C/O MATRIX CAPITAL MANAGEMENT
3 PLEASANT STREET, SUITE 400
(Street)
PORTSMOUTH NEW HAMPSHIRE 03801
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
GOEL DAVID E.
(Last)(First)(Middle)
C/O MATRIX CAPITAL MANAGEMENT CO., LP
3 PLEASANT STREET, SUITE 400
(Street)
PORTSMOUTH NEW HAMPSHIRE 03801
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.
2. The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Matrix Capital Management Company, LP, by: /s/ David E. Goel, its Managing General Partner05/11/2026
/s/ David E. Goel05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Aura Biosciences (AURA) recently report?

Aura Biosciences reported an open-market sale of 6,922,870 common shares at $5.64 each on May 7, 2026. The shares were held indirectly through a Matrix Capital–associated fund, and the filing shows zero shares remaining for this reported position.

Who was responsible for the Aura Biosciences (AURA) share sale in the Form 4?

The securities were held by Matrix Capital Management Master Fund, LP. Matrix Capital Management Company, LP acts as investment adviser, and David E. Goel is its managing general partner. They report the transaction but expressly disclaim beneficial ownership beyond any pecuniary interest.

How many Aura Biosciences (AURA) shares were sold and at what price?

The filing shows a sale of 6,922,870 shares of Aura Biosciences common stock at a price of $5.64 per share. This single open-market transaction represents the entire reported holding, with zero shares indicated as owned afterward.

Is the Aura Biosciences (AURA) insider sale a buy or sell direction overall?

The Form 4 reflects a clear net-sell direction. Transaction data show 6,922,870 shares sold and no shares acquired, resulting in net sell shares of 6,922,870 and a net-sell classification for the period covered by this filing.

What is the ownership nature of the Aura Biosciences (AURA) shares in this Form 4?

The shares are reported as indirectly owned, with the nature of ownership described by footnotes. The reporting persons state the securities are held by Matrix Capital Management Master Fund, LP and expressly disclaim beneficial ownership except to the extent of their pecuniary interest.